Chemical generation of bispecific antibodies (Q34450000)

2 August 2017

Chemical generation of bispecific antibodies (English)

1 reference

2 August 2017

1 reference

Venkata R Doppalapudi

1

1 reference

2 August 2017

Jie Huang

2

1 reference

2 August 2017

Dingguo Liu

3

1 reference

2 August 2017

Ping Jin

4

1 reference

2 August 2017

Bin Liu

5

1 reference

2 August 2017

Lingna Li

6

1 reference

2 August 2017

Joel Desharnais

7

1 reference

2 August 2017

Crystal Hagen

8

1 reference

2 August 2017

Nancy J Levin

9

1 reference

2 August 2017

Michael J Shields

10

1 reference

2 August 2017

Michelle Parish

11

1 reference

2 August 2017

Robert E Murphy

12

1 reference

2 August 2017

Joselyn Del Rosario

13

1 reference

2 August 2017

Bryan D Oates

14

1 reference

2 August 2017

Jing-Yu Lai

15

1 reference

2 August 2017

Marla J Matin

16

1 reference

2 August 2017

Zemeda Ainekulu

17

1 reference

2 August 2017

Abhijit Bhat

18

1 reference

2 August 2017

Curt W Bradshaw

19

1 reference

2 August 2017

Gary Woodnutt

20

1 reference

2 August 2017

Richard A Lerner

21

1 reference

2 August 2017

Rodney W Lappe

22

1 reference

2 August 2017

language of work or name

English

0 references

publication date

13 December 2010

1 reference

2 August 2017

6

1 reference

Proceedings of the National Academy of Sciences of the United States of America

inferred from page(s)

published in

1 reference

2 August 2017

107

1 reference

2 August 2017

22611-22616

1 reference

2 August 2017

52

1 reference

Targeting the ANGPT-TIE2 pathway in malignancy

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

New treatment approaches in renal cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

An efficient chemical approach to bispecific antibodies and antibodies of high valency

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Bevacizumab in the treatment of metastatic breast cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Treatment in advanced colorectal cancer: what, when and how?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Site-specific polysialylation of an antitumor single-chain Fv fragment.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Targeted cancer therapeutics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Hypoxia-induced up-regulation of angiopoietin-2 in colorectal cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

The place of VEGF inhibition in the current management of renal cell carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

VEGF as a key mediator of angiogenesis in cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Expression and significance of angiopoietin-2 in gastric cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

The biology of VEGF and its receptors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

High avidity scFv multimers; diabodies and triabodies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Immune versus natural selection: antibody aldolases with enzymic rates but broader scope

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Generation of bispecific and tandem diabodies

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

FDA approves sorafenib for patients with inoperable liver cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3012461

Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma

27 October 2018

1 reference

12 December 2020

Accessing the Kabat antibody sequence database by computer

1 reference

12 December 2020

Bevacizumab and chemotherapy improves survival in NSCLC

1 reference

12 December 2020

Bispecific antibodies: molecules that enable novel therapeutic strategies

1 reference

12 December 2020

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation

1 reference

12 December 2020

Single-chain antibodies as diagnostic tools and therapeutic agents

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.1016478108

1 reference

2 August 2017

0 references

1 reference

2 August 2017

1 reference